Abstract
Increased incidence rates of narcolepsy type 1 (NT1) after the 2009-2010 H1N1 influenza pandemic (pH1N1) have been reported world-wide. While some European countries found an association between the NT1 increase and H1N1 vaccination Pandemrix, reports from Asian countries suggested the H1N1 virus rather than Pandemrix to be linked with the increase of new NT1 cases. We analyzed the number of de-novo NT1 cases in the last two decades until 2016 using the European Narcolepsy Network (EU-NN) database. Using robust data-driven modelling approaches we confirmed the peak of NT1 incidence in 2009-2010 pH1N1 and identified a new peak in 2013 that is age-specific for children/adolescents. Most of these de-novo cases showed a subacute disease onset consistent with an immune-mediated type of narcolepsy, which is most likely not related to Pandemrix vaccination that was used in 2009-2010, but may have been triggered by some new epidemiological event in Europe. Our finding of an unexpected peak in de-novo children narcolepsy in 2013 provides a unique opportunity to develop new hypotheses, such as considering other (influenza) viruses to further investigate the pathophysiology of immune-mediated narcolepsy.
Competing Interest Statement
The following authors listed below disclose that : Dr. Ramin Khatami: international UCB narcolepsy advisory board; Dr. Claudio Bassetti: international UCB narcolepsy advisory board, international Jazz advisory board, consultation fees/speaker honoraria for Servier, Vifor, Zambon; Dr. Yves Dauvilliers: received funds for speaking and board engagements with UCB Pharma Brussels, Jazz Pharmaceuticals, USA and Bioprojet, France; Dr. Michel Lecendreux: received funds for speaking and board engagements with UCB Pharma, Jazz Pharmaceuticals, and Bioprojet; Dr. Geert Mayer: received honoraria for classifying narcolepsy cases for the Paul Ehrlich Institut, Langen, Germany; a member of the narcolepsy advisory board for UCB Pharma Brussels; PI for narcolepsy and sleep apnea studies in Germany for Jazz Pharmaceuticals, USA; investigator for the evaluation of polysomnographies in the Pre Parkinson’s Progression Markers Initiative by the Michael J. Fox Foundation, NY, USA; Dr. Guiseppe Plazzi: advisory board member for UCB Pharma and Jazz Pharmaceuticals; Dr. Karel Sonka: received speaker honoraria for Novartis and consultation fees for clinical trials for Bioprojet and Eisai; Dr. Peter Young: member of national advisory board for MEDICE and UCB Pharma Brussels, and received speaker honoraria for UCB; PI for narcolepsy study sponsored by UCB, PI for narcolepsy and sleep apnea studies sponsored by Jazz Pharmaceuticals, USA; Dr. Gert Jan Lammers: international UCB narcolepsy advisory board; Dr. Johannes Mathis: received speaker honoraria from UCB Switzerland. The other authors have nothing to disclose.
Funding Statement
The EU-NN database is financed by the EU-NN. The EU-NN has received financial support from UCB Pharma Brussels for developing the EU-NN database.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
